KR20230086143A - Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it - Google Patents
Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it Download PDFInfo
- Publication number
- KR20230086143A KR20230086143A KR1020210174492A KR20210174492A KR20230086143A KR 20230086143 A KR20230086143 A KR 20230086143A KR 1020210174492 A KR1020210174492 A KR 1020210174492A KR 20210174492 A KR20210174492 A KR 20210174492A KR 20230086143 A KR20230086143 A KR 20230086143A
- Authority
- KR
- South Korea
- Prior art keywords
- akkermansia
- genus
- culturing
- medium composition
- microorganisms
- Prior art date
Links
- 238000012258 culturing Methods 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000001963 growth medium Substances 0.000 title claims description 21
- 238000004108 freeze drying Methods 0.000 title claims description 5
- 241000099289 Akkermansia sp. Species 0.000 title 1
- 244000005700 microbiome Species 0.000 claims abstract description 59
- 241000702460 Akkermansia Species 0.000 claims abstract description 55
- 239000013028 medium composition Substances 0.000 claims abstract description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 40
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 20
- 239000012138 yeast extract Substances 0.000 claims abstract description 19
- 239000004473 Threonine Substances 0.000 claims abstract description 18
- 229960002898 threonine Drugs 0.000 claims abstract description 18
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 17
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 claims abstract description 14
- 235000021120 animal protein Nutrition 0.000 claims abstract description 12
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 8
- 241000702462 Akkermansia muciniphila Species 0.000 claims abstract description 7
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 26
- 239000008101 lactose Substances 0.000 claims description 23
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 15
- 230000000813 microbial effect Effects 0.000 claims description 14
- 239000012137 tryptone Substances 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 150000005846 sugar alcohols Chemical class 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 235000019260 propionic acid Nutrition 0.000 claims description 9
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
- 235000019270 ammonium chloride Nutrition 0.000 claims description 5
- 230000000959 cryoprotective effect Effects 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 2
- 229940111688 monobasic potassium phosphate Drugs 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 abstract description 16
- 230000001580 bacterial effect Effects 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 description 41
- 230000000052 comparative effect Effects 0.000 description 18
- 239000002609 medium Substances 0.000 description 15
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 10
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 239000004201 L-cysteine Substances 0.000 description 5
- 235000013878 L-cysteine Nutrition 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 244000005702 human microbiome Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FLNKWZNWHZDGRT-UHFFFAOYSA-N azane;dihydrochloride Chemical compound [NH4+].[NH4+].[Cl-].[Cl-] FLNKWZNWHZDGRT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- -1 that is Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
본 발명은 난배양성 혐기성 미생물 배양용 배지 조성물, 그를 이용한 배양방법, 및 그를 이용하여 제조된 동결건조 분말의 제조방법을 제공하기 위한 것이다.The present invention is to provide a medium composition for culturing egg-cultivated anaerobic microorganisms, a culture method using the same, and a method for producing a freeze-dried powder prepared using the same.
인간 마이크로바이옴이란 인간의 몸에 공생하는 미생물 군집과 이러한 미생물 군집의 유전체를 의미하는 용어로, 마이크로바이옴이 인간의 건강과 긴밀한 상관관계가 있음이 밝혀지고 있다. The human microbiome is a term that refers to a community of microorganisms that live symbiotically in the human body and the genome of such a community of microorganisms, and it has been revealed that the microbiome is closely related to human health.
인간 마이크로바이옴을 구성하는 미생물은 인간의 장 내부가 혐기 상태이므로, 대부분 혐기성 미생물이며, 그들 중 아커만시아(Akkermansia)속 미생물, 특히 아커만시아 뮤니시필라(Akkermansia muciniphila)는 한국특허 제1809172호에서 대사성 질환의 치료에 효과가 있는 것으로 밝혀진 바 있고, 또한 한국특허 제1799829호에서 퇴행성 뇌질환의 치료에도 효과가 있는 것으로 알려지고 있다.Since the microorganisms constituting the human microbiome are anaerobic in the human intestine, most of them are anaerobic microorganisms, and among them, Akkermansia genus microorganisms, especially Akkermansia muciniphila , are Korean Patent No. 1809172 It has been found to be effective in the treatment of metabolic diseases in Ho, and is also known to be effective in the treatment of degenerative brain diseases in Korean Patent No. 1799829.
상기 아커만시아속 미생물은 산소에 극도로 민감한 절대 혐기성 미생물로서, 일반적인 배지에 탄소원과 질소원으로서 돼지의 위에서 추출된 뮤신(hog gastric mucin)을 첨가하여 배양할 수 있고(Derrien et al., 2004), 콜럼비아 브로스(CB) 및 뇌심장침출액 (BHI) 브로스 상에서 뮤신을 첨가하여 배양할 수 있다고 알려져 있으나, 이용가능한 탄소원과 질소원이 매우 제한적이므로 산업적으로 유용한 정도로 생산 수율이 높고, 또한 경제적으로 대량생산하는 것은 극히 어려운 실정이다.The Akkermansia genus microorganisms are obligate anaerobic microorganisms that are extremely sensitive to oxygen, and can be cultured by adding hog gastric mucin extracted from the stomach of pigs as carbon and nitrogen sources to a general medium (Derrien et al., 2004) , It is known that mucin can be added and cultured on Columbia broth (CB) and brain heart extract (BHI) broth, but the available carbon and nitrogen sources are very limited, so the production yield is high to an industrially useful extent, and economically mass-produced It is an extremely difficult situation.
미국특허 제10,988,809호는 단당류로 글루코오스, N-에세틸헥소사민, 트레오닌 및 식물 단백질 가수분해물을 포함하는 배지를 이용한 아커만시아 뮤니시필라의 배양 방법을 제시하고 있고, 한국특허 제2222953호는 탄소원으로 프럭토오스 및 락토오스, N-아세틸헥소사민, L-아스파르트산, L-시스테인 및 식물 펩톤 등을 포함하는 배지를 제시하고 있으나, 생산 수율이 높고 경제적인 아커만시아속 미생물 배양용 배지 개발에 대한 요구가 여전히 존재하고 있다.U.S. Patent No. 10,988,809 proposes a method for culturing Ackermansia municipilla using a medium containing glucose, N-acetylhexosamine, threonine and plant protein hydrolysates as monosaccharides, and Korean Patent No. 2222953 discloses a carbon source As a medium containing fructose and lactose, N-acetylhexosamine, L-aspartic acid, L-cysteine and plant peptone, etc. are proposed, but the production yield is high and economic medium for culturing Akkermansia genus microorganisms has been developed. The demand for is still there.
본 발명은 아커만시아속 미생물이 마이크로바이옴 치료제와 같은 의약, 다양한 질환 개선 또는 예방용 식품 또는 사료로 산업적으로 활용될 수 있도록, 생산 수율이 높고 경제적으로 대량 생산이 가능한 아커만시아 속 미생물, 특히 아커만시아 뮤니시필라 배양용 배지 조성물 및 그를 이용한 배양방법을 제공하는 것이고, 또한 그를 이용하여 제조된 생존율 및 안정성이 향상된 아카만시아속 미생물 동결건조 분말의 제조방법을 제공하기 위한 것이다.The present invention is a microorganism of the genus Akkermansia that can be economically mass-produced with high production yield so that the microorganism of the genus Akkermansia can be industrially used as a medicine such as a microbiome treatment, food or feed for improving or preventing various diseases, In particular, it is to provide a culture medium composition for culturing Ackermansia municipilla and a culture method using the same, and also to provide a method for producing a freeze-dried powder of a microorganism of the genus Acamancia with improved survival rate and stability prepared using the same.
본 발명은 N-아세틸헥소사민 및 L-트레오닌을 포함하는 아커만시아(Akkermansia) 속 미생물 배양용 배지 조성물에 있어서, 상기 배지 조성물은 탄소원으로 이당류, 및 질소원으로 동물성 단백질 가수분해물 및 효모 추출물을 포함하는 아커만시아속 미생물 배양용 배지 조성물에 관한 것이다.The present invention relates to a medium composition for culturing microorganisms of the genus Akkermansia containing N-acetylhexosamine and L-threonine, wherein the medium composition contains disaccharide as a carbon source and animal protein hydrolysate and yeast extract as a nitrogen source. It relates to a culture medium composition for culture of microorganisms belonging to the genus Akkermansia comprising.
상기 이당류는 락토오스이고, 상기 락토오스는 배지 조성물에서 유일 탄소원일 수 있다.The disaccharide is lactose, and the lactose may be the only carbon source in the medium composition.
상기 동물성 단백질 가수분해물은 트립톤일 수 있다.The animal protein hydrolyzate may be tryptone.
상기 배지 조성물은 코발아민을 더 포함할 수 있다.The medium composition may further include cobalamin.
상기 배지 조성물은 N-아세틸헥소사민 0.5-5 g/L, L-트레오닌 1-5 g/L, 효모 추출물 5-20 g/L, 락토오스 10-20 g/L, 트립톤 10-30 g/L, 코발아민 0.01-1 mg/L 및 L-시스테인 0.2-1 g/L 포함하는 것일 수 있다.The medium composition contains 0.5-5 g/L of N-acetylhexosamine, 1-5 g/L of L-threonine, 5-20 g/L of yeast extract, 10-20 g/L of lactose, and 10-30 g of tryptone. /L, 0.01-1 mg/L of cobalamin and 0.2-1 g/L of L-cysteine.
상기 배지 조성물은 제1인산칼륨 0.2-0.8 g/L, 제2인산나트륨 0.3-0.9 g/L, 염화암모늄 0.1-0.6 g/L, 염화마그네슘 0.05-0.4 g/L, 염화칼슘 0.05-0.4 g/L, 탄산수소나트륨 2-8 g/L을 더 포함하는 것일 수 있다.The medium composition contains monobasic potassium phosphate 0.2-0.8 g/L, dibasic sodium phosphate 0.3-0.9 g/L, ammonium chloride 0.1-0.6 g/L, magnesium chloride 0.05-0.4 g/L, calcium chloride 0.05-0.4 g/L. L, it may further include 2-8 g/L of sodium hydrogen carbonate.
또한 본 발명은 상기 배지 조성물에 아커만시아(Akkermansia)속 미생물을 접종하여 혐기 조건에서 배양하는 아커만시아속 미생물의 배양방법에 관한 것이다.In addition, the present invention relates to a method for culturing microorganisms of the genus Akkermansia in which the culture medium composition is inoculated with microorganisms of the genus Akkermansia and cultured under anaerobic conditions.
상기 아커만시아속 미생물은 아커만시아 뮤시니필라(Akkermansia muciniphila)일 수 있다.The Akkermansia genus microorganism may be Akkermansia muciniphila.
또한 본발명은 상기 배지 조성물에 아커만시아(Akkermansia)속 미생물을 접종하여 혐기 조건에서 배양하는 단계; 상기 배양하는 단계의 배양액으로부터 아커만시아속 미생물 균체를 회수하는 단계; 슈크로오스, 말토오스 및 트레할로오스 중에서 선택되는 어느 하나의 당 또는 당알코올; 및 프로피온산, 아세트산 및 뷰티린산 중에서 선택되는 어느 하나의 유기산을 포함하는 동결보호 조성물과 상기 아커만시아속 미생물 균체를 혼합하는 단계; 및 상기 미생물 균체, 당 또는 당알코올 및 유기산의 혼합물을 동결건조시키는 단계;를 포함하는 아커만시아속 미생물 동결건조 분말의 제조방법에 관한 것이다.In addition, the present invention comprises the steps of inoculating a microorganism of the genus Akkermansia in the culture medium composition and culturing under anaerobic conditions; Recovering microbial cells of the genus Akkermansia from the culture solution of the culturing step; any one sugar or sugar alcohol selected from sucrose, maltose and trehalose; and mixing a cryoprotection composition containing any one organic acid selected from propionic acid, acetic acid and butyric acid with the microorganism cells of the genus Akkermansia; And freeze-drying the mixture of the microbial cells, sugar or sugar alcohol and organic acid; relates to a method for producing a freeze-dried powder of microorganisms belonging to the genus Akkermansia, including.
상기 동결보호 조성물에서 상기 당 또는 당알코올은 1-40 중량%, 상기 유기산은 0.1- 20 중량% 및 잔부 물을 포함할 수 있다. In the cryoprotection composition, the sugar or sugar alcohol may include 1 to 40% by weight, the organic acid to 0.1 to 20% by weight, and the balance water.
상기 아커만시아속 미생물 균체 100 중량부에 대하여, 상기 동결보호 조성물 30-300 중량부 포함할 수 있다. 30-300 parts by weight of the cryoprotective composition may be included with respect to 100 parts by weight of the Akkermansia microbial cells.
본 발명의 아커만시아 속 미생물, 특히 아커만시아 뮤니시필라 배양용 배지 조성물 및 그를 이용한 배양방법은 마이크로바이옴 치료제와 같은 의약, 다양한 질환 개선 또는 예방용 식품 또는 사료로 산업적으로 활용될 수 있도록, 평판계수법에 의해서 측정되는 아커만시아속 미생물의 생균수가 2 X 1010 CFU/mL 이상의 세포 밀도에 도달할 정도로 생산 수율이 높고 경제적으로 대량 생산이 가능하도록 하고, 또한 본 발명의 동결건조 분말의 제조방법을 통해 아커만시아 속 미생물의 생존율 및 안정성을 증가시킴으로써, 의약, 유산균 제제, 유가공품 및 생균제 등에 광범위하게 이용될 수 있게 한다.A microorganism of the genus Akkermansia of the present invention, in particular, a culture medium composition for culturing Akkermansia municipilla and a culture method using the same can be used industrially as a medicine such as a microbiome treatment, food or feed for improving or preventing various diseases , The production yield is high enough to reach a cell density of 2
도 1은 실험예 3에서 본 발명의 실시예 및 비교예 1 및 2의 배지 조성물로 아커만시아 뮤시니필라를 10L 발효조에서의 생산했을 때의 배양 시간에 따른 흡광도 및 24 시간째의 생균수(CFU/mL)를 확인한 그래프이다.
도 2는 실험예 4에서 슈크로오스와 함께 프로피온산을 첨가하여 동결건조한 제조예 4-4 시료와 슈크로오스만 첨가하여 동결건조한 제조예 4-2의 보존기간에 따른 생존율, 즉 안정성을 비교하여 나타낸 그래프이다.Figure 1 shows the absorbance according to the incubation time and the viable cell count at 24 hours ( It is a graph confirming CFU/mL).
Figure 2 is a comparison of the survival rate, that is, stability, according to the storage period of Preparation Example 4-4 prepared by adding propionic acid with sucrose in Experimental Example 4 and lyophilized with Preparation Example 4-2 prepared by adding only sucrose and freeze-dried it's a graph
본 발명은 N-아세틸헥소사민 및 L-트레오닌을 포함하는 아커만시아(Akkermansia) 속 미생물 배양용 배지 조성물에 있어서, 상기 배지 조성물은 탄소원으로 이당류, 및 질소원으로 동물성 단백질 가수분해물 및 효모 추출물을 포함하는 생산 수율이 높고 경제적인 아커만시아속 미생물 배양용 배지 조성물에 관한 것이다.The present invention is a medium composition for culturing microorganisms of the genus Akkermansia containing N-acetylhexosamine and L-threonine, wherein the medium composition contains disaccharide as a carbon source, and animal protein hydrolysate and yeast extract as a nitrogen source. It relates to a medium composition for culturing microorganisms belonging to the genus Akkermansia, which has a high production yield and is economical.
본 명세서에서 용어 "배지" 또는 "배양용 배지"는 미생물 성장 또는 증식에 필요한 모든 영양소 및 필수 물리적 성장 파라미터를 함유하는 고체, 반고체 또는 액체 배지를 의미한다.As used herein, the term "medium" or "culture medium" refers to a solid, semi-solid or liquid medium containing all nutrients and essential physical growth parameters necessary for microbial growth or proliferation.
또한 미생물의 "배양" 또는 "성장"이라는 용어는 미생물 유기체를 이의 성장에 도움이 되는 조건 하에서 소정의 배양 배지 중에서 번식시킴으로써 이를 증대시키는 것을 의미한다.Also, the term "cultivation" or "growth" of a microorganism means to increase the microbial organism by propagating it in a given culture medium under conditions conducive to its growth.
상기 배지 조성물에서 N-아세틸헥소사민은 아커만시아속 미생물 배양에 뮤신을 대체하는 용도로 널리 사용되고 있고, 상기 N-아세틸헥소사민은 N-아세틸글루코사민(Glc-NAc) 및 N-아세틸갈락토사민(Gal-NAc) 중에서 선택할 수 있으며, 바람직하게는 N-아세틸글루코사민이다. 상기 배지 조성물에서 N-아세틸헥소사민을 0.5-5 g/L, 바람직하게는 1-3 g/L, 더욱 바람직하게는 1.5-2 gL로 포함할 수 있다. 본 발명의 배지 조성물은 뮤신 대체용으로 사용되는 고가의 N-아세틸헥소사민의 사용을 낮추면서도 고수율로 생산이 가능하므로 대량생산에서 경제성이 뛰어나다.In the medium composition, N-acetylhexosamine is widely used as a substitute for mucin in culture of microorganisms belonging to the genus Ackermansia, and the N-acetylhexosamine is N-acetylglucosamine (Glc-NAc) and N-acetylgal It can be selected from lactosamine (Gal-NAc), preferably N-acetylglucosamine. In the medium composition, N-acetylhexosamine may be included in an amount of 0.5-5 g/L, preferably 1-3 g/L, and more preferably 1.5-2 gL. The medium composition of the present invention is economically viable in mass production because it can be produced in high yield while reducing the use of expensive N-acetylhexosamine used as a substitute for mucin.
아커만시아속 미생물이 분해할 수 있는 뮤신은 세린, 트레오닌, 프롤린 및 시스테인이 풍부한 아미노산 서열로 구성되므로, 뮤신이 없는 배지에서 아커만시아속 미생물을 배양함에 있어서는 상기 아미노산들을 추가로 공급하는 것이 생산 수율 증대에 유리하다. 상기 아미노산들 중에서 특히 트레오닌의 공급이 중요하고, 그 중에서도 트레오닌과 시스테인을 복합하여 공급하는 것이 매우 중요하다. 상기 배지 조성물에서 L-트레오닌을 1-5 g/L, 바람직하게는 1.2-4 g/L, 더욱 바람직하게는 1.5-3 g/L로 포함할 수 있다. 또한 시스테인을 0.2-1 g/L, 바람직하게는 0.3-0.8 g/L, 더욱 바람직하게는 0.3-0.6 g/L로 포함할 수 있다. Since mucin that can be degraded by microorganisms of the genus Akkermansia is composed of amino acid sequences rich in serine, threonine, proline and cysteine, when culturing microorganisms of the genus Akkermansia in a mucin-free medium, additional supply of these amino acids produces production It is advantageous to increase yield. Among the above amino acids, the supply of threonine is particularly important, and among these, it is very important to supply a combination of threonine and cysteine. In the medium composition, L-threonine may be included at 1-5 g/L, preferably at 1.2-4 g/L, and more preferably at 1.5-3 g/L. It may also contain cysteine at 0.2-1 g/L, preferably at 0.3-0.8 g/L, and more preferably at 0.3-0.6 g/L.
상기 아미노산들 외에도 알라닌, 아르기닌, 아스파라긴, 아스파르트산, 글루탐산, 글루타민, 글리신, 히스티딘, 이소류신, 류신, 리신, 메티오닌, 페닐알라닌, 히드록시프롤린, 트립토판, 티로신, 및 발린을 추가로 공급할 수 있다. 상기 아미노산들도 상기 배지 조성물에, 필요할 경우 0.05-0.5 g/L로 포함할 수 있다. 상기 아미노산들은 바람직하게는 모두 L형이고, 아스파르트산이나 시스테인은 D형도 가능하다.In addition to the above amino acids, alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, hydroxyproline, tryptophan, tyrosine, and valine can be additionally supplied. The amino acids may also be included in the medium composition at 0.05-0.5 g/L, if necessary. All of the above amino acids are preferably L-forms, and aspartic acid or cysteine may be D-forms.
본 발명의 일 실시예에 따르면, 상기 이당류는 락토오스이고, 상기 락토오스는 배지 조성물에서 유일 탄소원일 수 있다. 본 발명의 배지 조성물은 유일 탄소원으로 락토오스를 단독으로 사용하는 것이 탄소원으로 글루코오스를 단독 또는 다른 탄소원과 복합하여 사용하는 것에 비해 생산 수율 증대에 유리하다. 상기 배지 조성물에서 유일 탄소원인 락토오스는 10-20 g/L, 바람직하게는 11-18 g/L, 더욱 바람직하게는 12-16 g/L 포함할 수 있다.According to one embodiment of the present invention, the disaccharide is lactose, and the lactose may be the only carbon source in the medium composition. In the medium composition of the present invention, using lactose alone as the sole carbon source is advantageous in increasing production yield compared to using glucose alone or in combination with other carbon sources as the carbon source. In the medium composition, lactose, which is the sole carbon source, may be included at 10-20 g/L, preferably 11-18 g/L, and more preferably 12-16 g/L.
본 발명의 다른 실시예에 따르면, 상기 배지 조성물에서 배지 조성물은 질소원으로 동물성 단백질 가수분해물 및 효모 추출물을 복합 사용한다. 상기 동물성 단백질 가수분해물은 트립톤일 수 있다. 상기 효모 추출물은 효모 자가용해물 (autolysate), 한외여과된 효모 추출물 또는 합성 효모 추출물일 수 있다.According to another embodiment of the present invention, in the medium composition, animal protein hydrolysates and yeast extracts are used in combination as a nitrogen source. The animal protein hydrolyzate may be tryptone. The yeast extract may be yeast autolysate, ultrafiltered yeast extract or synthetic yeast extract.
질소원으로 소이 펩톤과 같은 식물 펩톤을 효모 추출물과 사용하는 것에 비해서 유단백질인 카제인을 트립신으로 가수분해한 동물성 단백질 가수분해물, 즉 트립톤을 효모 추출물과 복합 사용하는 것이 생산 수율 증대에 유리하고, 특히 유일 탄소원으로 락토오스를 사용하는 경우, 질소원으로 트립톤 및 효모 추출물을 복합 사용하는 것이 생산 수율 증대에 더욱 현저히 유리하다. 상기 배지 조성물에서 동물성 단백질 가수분해물은 10-30 g/L, 바람직하게는 11-25 g/L, 더욱 바람직하게는 12-20 g/L 포함할 수 있고, 효모 추출물은 5-20 g/L, 바람직하게는 7-18 g/L, 더욱 바람직하게는 9-16 g/L 포함할 수 있다.Compared to using plant peptone such as soy peptone with yeast extract as a nitrogen source, using animal protein hydrolysate obtained by hydrolyzing casein, a milk protein, with trypsin, that is, tryptone in combination with yeast extract is advantageous in increasing production yield. When lactose is used as a carbon source, it is more significantly advantageous to increase production yield to use a combination of tryptone and yeast extract as a nitrogen source. In the medium composition, the animal protein hydrolyzate may be included at 10-30 g/L, preferably 11-25 g/L, and more preferably 12-20 g/L, and the yeast extract at 5-20 g/L , preferably 7-18 g/L, more preferably 9-16 g/L.
본 발명의 다른 실시예에 따르면, 상기 배지 조성물은 코발아민을 더 포함할 수 있다. 상기 배지 조성물에서 코발아민은 0.01-1 mg/L, 바람직하게는 0.05-0.5 mg/L, 더욱 바람직하게는 0.08-0.12 mg/L 포함할 수 있다.According to another embodiment of the present invention, the medium composition may further include cobalamin. In the medium composition, cobalamin may be included in an amount of 0.01-1 mg/L, preferably 0.05-0.5 mg/L, and more preferably 0.08-0.12 mg/L.
본 발명의 다른 실시예에 따르면, 상기 배지 조성물은 N-아세틸헥소사민 1-5 g/L, L-트레오닌 1-5 g/L, 효모 추출물 5-20 g/L, 락토오스 10-20 g/L, 트립톤 10-30 g/L, 코발아민 0.001-1 mg/L 및 L-시스테인 0.2-1 g/L 포함하는 것일 수 있다.According to another embodiment of the present invention, the medium composition contains 1-5 g/L of N-acetylhexosamine, 1-5 g/L of L-threonine, 5-20 g/L of yeast extract, and 10-20 g of lactose. /L, tryptone 10-30 g/L, cobalamin 0.001-1 mg/L, and L-cysteine 0.2-1 g/L.
본 발명의 다른 실시예에 따르면, 상기 배지 조성물은 제1인산칼륨 0.2-0.8 g/L, 제2인산나트륨 0.3-0.9 g/L, 염화암모늄 0.1-0.6 g/L, 염화마그네슘 0.05-0.4 g/L, 염화칼슘 0.05-0.4 g/L, 탄산수소나트륨 2-8 g/L을 더 포함하는 것일 수 있다.According to another embodiment of the present invention, the medium composition contains 0.2-0.8 g/L of potassium phosphate monobasic, 0.3-0.9 g/L of sodium phosphate dibasic, 0.1-0.6 g/L of ammonium chloride, and 0.05-0.4 g of magnesium chloride. /L, calcium chloride 0.05-0.4 g/L, and sodium bicarbonate 2-8 g/L may be further included.
본 발명의 다른 실시예에 따르면, 상기 배지 조성물은 트립톤(Hydrolysed Casein Protein) 15 g/L, 효모 추출물(Yeast extract) 10 g/L, L-트레오닌(L-Threonine) 2 g/L, 락토스(lactose) 13.512 g/L, N-아세틸헥소사민 1.659 g/L, 인산칼륨(Monopotassium Phosphate [KH2PO4]) 0.4 g/L, 인산나트륨(Disodium Phosphate FG [Na2HPO4]) 0.53 g/L, 염화암모니움(Ammonium Chloride [NH4Cl]) 0.3 g/L, 염화마그네슘(Magnesium Chloride [MgCl2]) 0.1 g/L, 염화칼슘(Cacium Chloride [CaCl2]) 0.11 g/L, 중탄산염나트륨(Sodium Bicarbonate [NaHCO3]) 4 g/L, 시아노코발아민 (Cyanocobalamin) 0.0001 g/L, L-시스테인 (L-Cystein), 0.5 g/L 을 함유할 수 있다.According to another embodiment of the present invention, the medium composition contains 15 g/L of hydrolysed casein protein, 10 g/L of yeast extract, 2 g/L of L-threonine, and lactose. (lactose) 13.512 g/L, N-acetylhexosamine 1.659 g/L, Monopotassium Phosphate [KH2PO4] 0.4 g/L, Sodium Phosphate FG [Na2HPO4] 0.53 g/L, Ammonium chloride Ammonium Chloride [NH4Cl] 0.3 g/L, Magnesium Chloride [MgCl2] 0.1 g/L, Cacium Chloride [CaCl2] 0.11 g/L, Sodium Bicarbonate [NaHCO3] 4 g/L, Cyanocobalamin 0.0001 g/L, L-Cysteine, 0.5 g/L.
상기 배지 조성물은 액체 배지뿐만 아니라, 분말 또는 농축된 액체 배지일 수 있다. 이 경우 사용 전 소정의 부피의 물, 보통 멸균수에 용해될 수 있다.The medium composition may be a liquid medium as well as a powder or concentrated liquid medium. In this case, it can be dissolved in a predetermined volume of water, usually sterile water, before use.
또한 본 발명은 상기 배지 조성물에 아커만시아(Akkermansia)속 미생물을 접종하여 혐기 조건에서 배양하는 아커만시아속 미생물의 배양방법에 관한 것이다.In addition, the present invention relates to a method for culturing microorganisms of the genus Akkermansia in which the medium composition is inoculated with microorganisms of the genus Akkermansia and cultured under anaerobic conditions.
본 발명의 일 실시예에 따르면, 상기 아커만시아속 미생물은 아커만시아 뮤시니필라(Akkermansia muciniphila)일 수 있다.According to one embodiment of the present invention, the microorganism of the genus Akkermansia may be Akkermansia muciniphila.
상기 배양은 pH 6.0 ~ 8.0, 배양온도 35 ~ 40℃교반속도 20 ~ 120 rpm, 질소포화도 100%의 조건에서 실시할 수 있다. The culturing may be carried out under conditions of pH 6.0 to 8.0, culture temperature of 35 to 40° C., stirring speed of 20 to 120 rpm, and nitrogen saturation of 100%.
본 발명에 따르면 본 발명의 배지 조성물을 이용하여 배양할 경우 평판계수법에 의해서 측정되는 아커만시아속 미생물의 생균수가 2 X 1010 CFU/mL 이상의 세포 밀도에 도달할 정도로 생산 수율이 뛰어나다.According to the present invention, when cultured using the medium composition of the present invention, the production yield is excellent enough to reach a cell density of 2
또한 본 발명은 상기 배지 조성물에 아커만시아(Akkermansia)속 미생물을 접종하여 혐기 조건에서 배양하는 단계; 상기 배양하는 단계의 배양액으로부터 아커만시아속 미생물 균체를 회수하는 단계; 슈크로오스, 말토오스 및 트레할로오스 중에서 선택되는 어느 하나의 당 또는 당알코올; 및 프로피온산, 아세트산 및 뷰티린산 중에서 선택되는 어느 하나의 유기산을 포함하는 동결보호 조성물과 상기 아커만시아속 미생물 균체를 혼합하는 단계; 및 상기 상기 미생물 균체, 당 또는 당알코올 및 유기산의 혼합물을 동결건조시키는 단계;를 포함하는 아커만시아속 미생물 동결건조 분말의 제조방법에 관한 것이다. In addition, the present invention comprises the step of inoculating a microorganism of the genus Akkermansia in the culture medium composition and culturing under anaerobic conditions; Recovering microbial cells of the genus Akkermansia from the culture solution of the culturing step; any one sugar or sugar alcohol selected from sucrose, maltose and trehalose; and mixing a cryoprotection composition containing any one organic acid selected from propionic acid, acetic acid and butyric acid with the microorganism cells of the genus Akkermansia; And freeze-drying the mixture of the microbial cells, sugar or sugar alcohol, and organic acid; relates to a method for producing a freeze-dried powder of microorganisms belonging to the genus Akkermansia, including.
상기 동결보호 조성물에서 당 또는 당알코올의 함량은 1-40 중량%, 바람직하게는 5-30 중량%, 더욱 바람직하게는 7-20 중량%이고, 상기 유기산은 0.1- 20 중량%, 바람직하게는 1 내지 15 중량%, 더욱 바람직하게는 3-10 중량% 포함할 수 있고, 필요에 따라 다른 동결보호 성분을 포함할 수 있으며, 잔부는 물을 포함한다.In the cryoprotection composition, the content of sugar or sugar alcohol is 1-40% by weight, preferably 5-30% by weight, more preferably 7-20% by weight, and the organic acid is 0.1-20% by weight, preferably It may contain 1 to 15% by weight, more preferably 3-10% by weight, and may include other cryoprotective components as needed, the balance including water.
상기 아커만시아속 미생물 균체 100 중량부에 대하여, 상기 동결보호 조성물 30-300 중량부, 바람직하게는 50 내지 150 중량부 포함할 수 있다.Based on 100 parts by weight of the Akkermansia microbial cells, the cryoprotection composition may include 30-300 parts by weight, preferably 50 to 150 parts by weight.
상기 당 또는 당알코올은 바람직하게는 슈크로오스이고, 상기 유기산은 바람직하게는 프로피온산일 수 있다.The sugar or sugar alcohol is preferably sucrose, and the organic acid may be preferably propionic acid.
상기 방법으로부터 생산된 아커만시아속 미생물 동결건조 분말은 동결건조 전 시료 대비 생존율(viability)가 40% 이상이다. 상기 생존율은 전체 균수 대비 생존 균수의 %로 나타낸다. 또한 상기 방법으로부터 생산 후 실온에서 6개월 이상, 바람직하게는 1년 보관 후 측정한 안정성(stability)는 최초 생균수 대비 90% 이상이다.The freeze-dried powder of Akkermansia genus microorganisms produced by the above method has a viability of 40% or more compared to the sample before freeze-drying. The survival rate is expressed as a percentage of the number of viable bacteria relative to the total number of bacteria. In addition, the stability measured after storage at room temperature for 6 months or more, preferably 1 year after production from the above method is 90% or more compared to the initial viable cell count.
이하 본 발명을 실시예를 통해 더욱 상세하게 설명하나, 본 발명이 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples, but the present invention is not limited thereto.
[제조예 1][Production Example 1]
아래 표 1과 같이 제조예 1-1 내지 1-3의 배지 조성물을 제조하였다. 제조예 1-1 및 1-3은 유일 탄소원으로 글루코오스를 사용한 배지이고, 제조예 1-2는 유일 탄소원으로 글루코오스를 대체하여 락토오스를 사용한 것이며, 제조예 1-1 및 1-2는 질소원으로 효모 추출물과 함께 식물 펩톤인 소이 펩톤(Soytone)을 사용한 것이고, 제조예 1-3은 식물 펩톤을 대체하여 동물성 단백질 가수분해물인 트립톤을 사용한 것이다.Media compositions of Preparation Examples 1-1 to 1-3 were prepared as shown in Table 1 below. Preparation Examples 1-1 and 1-3 are media using glucose as the sole carbon source, Preparation Example 1-2 is a medium using lactose by replacing glucose as the sole carbon source, Preparation Examples 1-1 and 1-2 are yeast as a nitrogen source Soy peptone, a plant peptone, was used together with the extract, and in Preparation Examples 1-3, tryptone, an animal protein hydrolyzate, was used instead of plant peptone.
[실험예 1][Experimental Example 1]
제조예 1-1 및 제조예 1-2의 배지 조성물에 아커만시아 뮤니시필라 균주를 1% (v/v) 농도로 접종한 후, pH 7.0, 배양온도 37℃교반속도 80 rpm, 질소포화도 100% 조건에서 24 시간 배양하였다. After inoculating the Ackermansia municipilla strain at a concentration of 1% (v / v) in the medium composition of Preparation Example 1-1 and Preparation Example 1-2, pH 7.0,
아커만시아 뮤니시필라 균주는 DSM 22959 균주(이하 'HB01' 균주라고도 함) 및 본 출원인이 보유하고 있는 KCCM12318P 균주(이하 HB03 균주라고도 함), KCCM12424P 균주(이하 HB05 균주라고도 함)을 사용하였다.As the Ackermansia municipilla strain, DSM 22959 strain (hereinafter referred to as 'HB01' strain), KCCM12318P strain (hereinafter referred to as HB03 strain) and KCCM12424P strain (hereinafter referred to as HB05 strain) possessed by the present applicant were used.
24 시간째 배양액의 흡광도(600 nm OD)를 측정하여 표 2에 나타내고, Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) 장비를 이용한 총균수 계수 방법으로 측정된 배양액의 전체 균수(cell/mL) 측정하여 표 3에 나타내며, 상기 배양액을 평판계수법에 의해서 생균수(CFU/mL)를 측정하여 표 4에 나타내었다.At 24 hours, the absorbance (600 nm OD) of the culture medium was measured and shown in Table 2, and the total number of bacteria (cell / mL) of the culture medium measured by the total number of bacteria count method using Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) equipment It is measured and shown in Table 3, and the number of viable cells (CFU / mL) of the culture medium is measured by the plate counting method and shown in Table 4.
a: student's t-test에 의해 P<0.05로 유의하게 값이 나옴 / b: 유의하게 값이 나오지 않음동일 균주에서 배지의 차이에 따른 통계적으로 유의함을 판단하기 위하여 student's t-test 방법을 사용하여 p값이 0.05 미만인 경우에만 통계적으로 유의미한 것으로 판단하였고, 이하 동일하게 유의차를 표시하였다.a: Significant value as P<0.05 by student's t-test / b: No significant value In order to determine statistical significance according to the difference in medium in the same strain, use the student's t-test method Only when the p value was less than 0.05 was determined to be statistically significant, and the same significant difference was indicated below.
3종의 아커만시아 뮤니시필라 균주 모두에서 유일 탄소원으로 글루코오스를 이용하는 제조예 1-1에 비해 락토오스를 이용하는 제조예 1-2의 배지 조성물이 흡광도, 전체 균수 및 생균수 모두를 증가시키는 경향을 나타내었다. Compared to Preparation Example 1-1 using glucose as the sole carbon source in all three Ackermansia municipilla strains, the medium composition of Preparation Example 1-2 using lactose tends to increase both absorbance, total bacterial count and viable cell count showed up
다만 락토오스를 이용하는 제조예 1-2에서 글루코오스를 이용하는 제조예 1-1에 비해HB05균주에서만 유의적으로 흡광도를 증가시켰고, 전체 균수는 HB01, HB03 및 HB05 모든 균주에서 전체 균주를 유의적으로 증가시켰고, 생균수는 HB01 및 HB05균주만을 유의적으로 증가시켜, 아커만시아 뮤니시필라 균주의 종류에 따라 차이를 나타내었다.However, in Preparation Example 1-2 using lactose, compared to Preparation Example 1-1 using glucose, only the HB05 strain significantly increased the absorbance, and the total number of bacteria significantly increased all strains in all strains HB01, HB03 and HB05 , The number of viable cells significantly increased only in strains HB01 and HB05, showing differences depending on the type of Ackermansia municipilla strain.
[실험예 2][Experimental Example 2]
제조예 1-1 및 제조예 1-3의 배지 조성물에 아커만시아 뮤니시필라 균주를 1% (v/v) 농도로 접종한 후, pH 7.0, 배양온도 37℃교반속도 80 rpm, 질소포화도 100% 조건에서 24 시간 배양하였다. After inoculating the Ackermansia municipilla strain at a concentration of 1% (v / v) in the medium composition of Preparation Example 1-1 and Preparation Example 1-3, pH 7.0,
아커만시아 뮤니시필라 균주는 DSM 22959 균주(이하 'HB01' 균주라고도 함) 및 본 출원인이 보유하고 있는 KCCM12318P 균주(이하 HB03 균주라고도 함), KCCM12424P 균주(이하 HB05 균주라고도 함)을 사용하였다.As the Ackermansia municipilla strain, DSM 22959 strain (hereinafter referred to as 'HB01' strain), KCCM12318P strain (hereinafter referred to as HB03 strain) and KCCM12424P strain (hereinafter referred to as HB05 strain) possessed by the present applicant were used.
24 시간째 배양액의 흡광도(600 nm OD)를 측정하여 표 5에 나타내고, Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) 장비를 이용한 총균수 계수 방법으로 측정된 배양액의 전체 균수(cell/mL) 측정하여 표 6에 나타내며, 상기 배양액을 평판계수법에 의해서 생균수(CFU/mL)를 측정하여 표 7에 나타내었다.At 24 hours, the absorbance (600 nm OD) of the culture medium was measured and shown in Table 5, and the total number of bacteria (cell / mL) of the culture medium measured by the total number of bacteria count method using Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) equipment It is measured and shown in Table 6, and the number of viable cells (CFU / mL) of the culture medium is measured by the plate counting method and shown in Table 7.
3종의 아커만시아 뮤니시필라 균주 모두에서 식물 펩톤을 질소원으로 이용하는 제조예 1-1에 비해 트립톤을 질소원으로 이용하는 1-3이 흡광도, 전체 균수 및 생균수 모두를 증가시키는 경향을 나타내었다. Compared to Preparation Example 1-1 using plant peptone as a nitrogen source in all three Ackermansia municipilla strains, 1-3 using tryptone as a nitrogen source showed a tendency to increase absorbance, total bacterial count, and viable cell count. .
다만 락토오스를 이용하는 제조예 1-2에서 글루코오스를 이용하는 제조예 1-1에 비해HB01균주에서만 유의적으로 흡광도를 증가시켰고, 전체 균수는 HB01, HB03 및 HB05 모든 균주에서 전체 균주를 유의적으로 증가시켰고, 생균수는 HB01, HB03 및 HB05 모든 균주에서 유의적인 증가는 나타내지 않아 아커만시아 뮤니시필라 균주의 종류에 따라 차이를 나타내었다.However, compared to Preparation Example 1-1 using glucose in Preparation Example 1-2 using lactose, only the HB01 strain significantly increased the absorbance, and the total number of bacteria significantly increased all strains in all strains HB01, HB03 and HB05 , The number of viable cells did not show a significant increase in all strains of HB01, HB03 and HB05, indicating differences depending on the type of Ackermansia municipilla strain.
[제조예 2][Production Example 2]
아래 표 8과 같이 실시예 및 비교예 1 및 2의 배지 조성물을 제조하였다. 실시예는 제조예 1-1의 기본 배지에서 유일 탄소원으로 글루코오스를 대체하여 락토오스를 사용하는 동시에, 질소원으로 동물성 단백질 가수분해물인 트립톤 및 효모 추출물을 복합 사용하고, 아미노산으로 L-트레오닌 및 L-시스테인을 추가한 것이다.Media compositions of Examples and Comparative Examples 1 and 2 were prepared as shown in Table 8 below. Example uses lactose by replacing glucose as the sole carbon source in the basal medium of Preparation Example 1-1, uses tryptone, which is an animal protein hydrolyzate, and yeast extract as nitrogen sources, and uses L-threonine and L-threonine as amino acids. cysteine was added.
비교예 1은 종래 공지된 아커만시아 뮤니시필라 배양용 배지 조성 중 하나로 유일 탄소원으로 글루코오스를 사용하고, 질소원으로 소이 펩톤(Soytone)을 사용하며, 아미노산으로 L-트레오닌을 추가하는 특징을 가진 배지 조성물이다.Comparative Example 1 is one of the conventionally known culture medium compositions of Ackermansia municipilla, using glucose as the sole carbon source, using soy peptone as the nitrogen source, and adding L-threonine as an amino acid. is a composition
비교예 2도 종래 공지된 아커만시아 뮤니시필라 배양용 배지 조성 중 하나로 탄소원으로프락토오스와 락토오스를 복합 사용하고, 또한 질소원으로 식물 펩톤을 효모 추출물과 복합사용하고, 아미노산으로 L-아스파르트산 및 L-시스테인을 추가 투입하는 특징을 가진 배지 조성물이다.Comparative Example 2 also uses a combination of fructose and lactose as a carbon source as one of the previously known media compositions for culturing Ackermansia municipilla, and also uses a combination of plant peptone and yeast extract as a nitrogen source, and uses L-aspartic acid and L-aspartic acid as amino acids. It is a medium composition characterized by the addition of L-cysteine.
[실험예 2][Experimental Example 2]
제조예 2의 비교예 1 및 2, 실시예의 배지 조성물에 아커만시아 뮤니시필라 균주를 1% (v/v) 농도로 접종한 후, pH 7.0, 배양온도 37℃교반속도 80 rpm, 질소포화도 100% 조건에서 24 시간 배양하였다. 아커만시아 뮤니시필라 균주는 실험예 1과 동일하게 HB01, HB03 및 HB05 균주를 사용하였다. After inoculating the Ackermansia municiphila strain at a concentration of 1% (v / v) in the medium composition of Comparative Examples 1 and 2, Example of Preparation Example 2, pH 7.0,
Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) 장비를 이용한 총균수 계수 방법으로 측정된 배양액의 전체 균수(cell/mL) 측정하여 표 9에 나타내며, 상기 배양액을 평판계수법에 의해서 생균수(CFU/mL)를 측정하여 표 10에 나타내었다.The total bacterial count (cell / mL) of the culture medium measured by the total bacterial count method using the Automatic Cell counter (Tx Microbial Cell counter, Logos Biosystem) equipment is measured and shown in Table 9, and the viable cell count (CFU / mL) was measured and shown in Table 10.
a 또는 b: student's t-test에 의해 P<0.05로 유의하게 값이 나옴 / c: 유의하게 값이 나오지 않음동일 균주에서 배지의 차이에 따른 통계적으로 유의함을 판단하기 위하여 student's t-test 방법을 사용하여 p값이 0.05 미만인 경우에만 통계적으로 유의미한 것으로 판단하였고, 비교예 1및 2에 비해 실시예에서 p값이 0.05 미만인 경우를 각각 a 및 b로 표시하였다.a or b: significant value as P<0.05 by student's t-test / c: no significant value In order to determine statistical significance according to the difference in medium in the same strain, the student's t-test method was used It was determined that it was statistically significant only when the p value was less than 0.05, and cases where the p value was less than 0.05 in Examples compared to Comparative Examples 1 and 2 were indicated as a and b, respectively.
제조예 1-1의 기본 배지에서 글루코오스만 락토오스로 변경한 제조예 1-2 및 소이 펩톤을 트립톤으로 변경한 제조예 1-3에서는 전체 균주 및 생균수의 증가에 있어서 유의차가 아커만시아 뮤니시필라 균주의 종류에 따라 차이를 나타내었으나, 실시예의 배지에서는 기존 비교예 1 및 2의 배지에 비해서 모든 균주에서 전체 균주 및 생균수의 증가를 유의적으로 확인할 수 있었고, 그 양에 있어서도 최소 2배 이상으로 기존 배지에 비해 생산 수율이 현저히 증가함을 확인하였다.In Preparation Example 1-2 in which only glucose was changed to lactose in the basal medium of Preparation Example 1-1 and Preparation Example 1-3 in which soy peptone was changed to tryptone, there was a significant difference in the increase in total strains and viable cell counts. Although differences were shown depending on the type of Sipilla strain, in the medium of Example, a significant increase in the total number of strains and viable cells was confirmed in all strains compared to the medium of Comparative Examples 1 and 2, and the amount was at least 2 It was confirmed that the production yield was significantly increased compared to the conventional medium by more than two times.
[실험예 3][Experimental Example 3]
10 L 발효조로 스케일업하여 배양했을 경우의 실시예의 배지 조성물이 비교예 1 및 2의의 생산배지 조성물에 비해 수율 증대 효과를 나타내는 지 확인하기 위하여 실험예 3의 실험을 진행하였다. The experiment of Experimental Example 3 was conducted to confirm whether the medium composition of Example exhibits a yield increase effect compared to the production medium composition of Comparative Examples 1 and 2 when cultured by scale-up in a 10 L fermentor.
10L 발효조에서 제조예 2의 비교예 1 및 2, 실시예의 배지 조성물 각 7L에 아커만시아 뮤니시필라 균주를 1% (v/v) 농도로 접종한 후, pH 7.0, 배양온도 37℃교반속도 80 rpm, 질소포화도 100% 조건에서 48 시간 배양하였다. 아커만시아 뮤니시필라 균주는 HB03 균주를 사용하였다. In a 10L fermenter, each 7L of the medium composition of Comparative Examples 1 and 2 and Example of Preparation Example 2 was inoculated with the Ackermansia municophila strain at a concentration of 1% (v / v), pH 7.0,
매 시간마다 600 nm에서 흡광도(OD)를 측정하였고, 24 시간째 배양액을 평판계수법에 의해서 생균수(CFU/mL)를 측정하여 도 1에 도시하였다. 24시간째 각 배양액의 생균수는 실시예에서 2.02 X 1010 CFU/mL, 비교예 1에서 1.02 X 1010 CFU/mL 그리고 비교예 2에서 4.12 X 109 CFU/mL이었다. 실시예의 배지 조성물은 비교예 1에 비해 약 20 배, 비교예 2에 비해서는 약 2배 이상의 생균수 차이를 나타내었다.The absorbance (OD) was measured at 600 nm every hour, and the number of viable cells (CFU/mL) of the culture medium at 24 hours was measured by plate counting method, and is shown in FIG. 1 . At 24 hours, the number of viable cells in each culture was 2.02 X 10 10 CFU/mL in Example, 1.02 X 10 10 CFU/mL in Comparative Example 1, and 4.12 X 10 9 CFU/mL in Comparative Example 2. The medium composition of Example showed a difference in the number of viable cells by about 20 times compared to Comparative Example 1 and about 2 times or more compared to Comparative Example 2.
[실험예 4][Experimental Example 4]
실험예 3의 아커만시아 뮤니시필라 균주(HB03 균주) 24시간째 배양액을 혐기적 조건에서에서, 혐기 챔버로 옮긴 뒤 TFF (Tangential Flow Filtration) 시스템을 통해 균체를 회수하였다. TFF 시스템을 통해 균체만 농축시킨 후 농축이 완료된 HB03 균주 균체는 멸균된 병에 회수하였다. 상기 균체 100 중량부를 슈크로오스 및 프로피온산 함량을 변경하면서 정제수에 용해한 동결보호 조성물 80 중량부와 혼합한 후 시료를 각각 진공포장기로 입구만 밀봉하였다. 밀봉한 진공백은 챔버에서 꺼내고, deep freezer (-70℃)에서 예비 동결하고, 진공을 걸고 동결 작업을 24시간 진행하여 동결건조하였다.Ackermansia municipilla strain (strain HB03) of Experimental Example 3 At 24 hours, the culture medium was transferred to an anaerobic chamber under anaerobic conditions, and the cells were recovered through a Tangential Flow Filtration (TFF) system. After concentrating only the cells through the TFF system, the concentrated HB03 strain cells were collected in a sterilized bottle. 100 parts by weight of the cells were mixed with 80 parts by weight of the cryoprotective composition dissolved in purified water while changing the contents of sucrose and propionic acid, and then each sample was sealed with a vacuum packaging machine. The sealed vacuum bag was taken out of the chamber, pre-frozen in a deep freezer (-70 ° C), and freeze-dried by applying a vacuum and freezing for 24 hours.
동결건조 시료의 전체 균수 및 생균수는 실험예 1에 기재된 방법으로 측정하고, 생균수를 전체 균수로 나눈 값을 %로 나타낸 값을 생존율(viability)로 정의하고 표 11에 나타내었다.The total number of bacteria and the number of viable cells in the freeze-dried sample were measured by the method described in Experimental Example 1, and the value obtained by dividing the number of viable cells by the total number of bacteria in % was defined as the viability and is shown in Table 11.
±2.67 b 42.98
± 2.67b
제조예 4-1과 비교하여 제조예 4-2 내지 4-5의 통계적으로 유의함을 판단하기 위하여 student's t-test 방법을 사용하여 p값이 0.05 미만인 경우 a로 표시하고, p값이 0.005 미만인 경우 b로 표시하여 통계적으로 유의미한 것으로 판단하였다.제조예 4-1에 비해 슈크로오스의 중량을 2 배 증가시킬 경우 생존율이 다소 증가하는 경향을 나타내었으나, 통계적으로 유의미하지 않았다. 그러나 제조예 4-1에 비해 프로피온산을 첨가한 경우 생존율이 2 배 이상 현저하게 유의적으로 증가하였다(p<0.05).In order to determine the statistical significance of Preparation Examples 4-2 to 4-5 compared to Preparation Example 4-1, the student's t-test method is used to indicate a if the p value is less than 0.05, and the p value is less than 0.005 In case b, it was judged to be statistically significant. When the weight of sucrose was increased by 2 times compared to Preparation Example 4-1, the survival rate showed a tendency to increase slightly, but it was not statistically significant. However, when propionic acid was added compared to Preparation Example 4-1, the survival rate significantly increased more than twice (p<0.05).
제조예 4-3보다 슈크로오스의 함량을 6.0 중량%, 8.8 중량%로 증가시킨 제조예 4-4 및 4-5는 생존율이 더욱 증가하는 경향을 나타내었고, 제조예 4-1에 비해 생존율이 3 배 이상 현저하게 유의적으로 증가하였다(p<0.005).Preparation Examples 4-4 and 4-5 in which the content of sucrose was increased to 6.0% by weight and 8.8% by weight compared to Preparation Example 4-3 showed a tendency to increase the survival rate more, and the survival rate compared to Preparation Example 4-1 This significantly increased more than 3 times (p<0.005).
상기 제조예 4-2 및 4-4 시료를 실온(20 ℃)에 보관하면서 생존율을 측정하고, 최초 생존율 기준으로 보존기간에 따른 상대적인 생존율의 변화를 안정정(stability)로 계산하여 도 2에 나타내었다. The viability was measured while the samples of Preparation Examples 4-2 and 4-4 were stored at room temperature (20 ° C), and the change in relative survival rate according to the storage period was calculated as stability based on the initial survival rate, and it is shown in FIG. .
도 2에 따르면 제조예 4-2 시료의 경우 최초 생존율에서 6개월 후 생존율을 47% 감소하였고, 제조예 4-4 시료의 경우 최초 생존율에서 6개월 후 생존율이 8%만 감소하여 동결건조 전 슈크로오스와 프로피온산을 복합한 경우 보존 안정성이 현저히 우수하였다.According to FIG. 2, in the case of the sample of Preparation Example 4-2, the survival rate after 6 months from the initial survival rate decreased by 47%, and in the case of the sample of Preparation Example 4-4, the survival rate decreased by only 8% after 6 months from the initial survival rate. Storage stability was remarkably excellent when lozose and propionic acid were combined.
Claims (11)
상기 배지 조성물은 탄소원으로 이당류, 및 질소원으로 동물성 단백질 가수분해물 및 효모 추출물을 포함하는 아커만시아속 미생물 배양용 배지 조성물.In the medium composition for culturing microorganisms of the genus Akkermansia containing N-acetylhexosamine and L-threonine,
The medium composition is a medium composition for culturing microorganisms belonging to the genus Akkermansia comprising disaccharides as a carbon source, and animal protein hydrolysates and yeast extracts as nitrogen sources.
상기 배양하는 단계의 배양액으로부터 아커만시아속 미생물 균체를 회수하는 단계;
슈크로오스, 말토오스 및 트레할로오스 중에서 선택되는 어느 하나의 당 또는 당알코올; 및 프로피온산, 아세트산 및 뷰티린산 중에서 선택되는 어느 하나의 유기산을 포함하는 동결보호 조성물과 상기 아커만시아속 미생물 균체를 혼합하는 단계; 및
상기 미생물 균체, 당 또는 당알코올 및 유기산의 혼합물을 동결건조시키는 단계;를포함하는 아커만시아속 미생물 동결건조 분말의 제조방법.Claims 1 to 6 of any one of the culture medium composition Akkermansia ( Akkermansia ) Step of inoculating a microorganism of the genus and culturing under anaerobic conditions;
Recovering microbial cells of the genus Akkermansia from the culture solution of the culturing step;
any one sugar or sugar alcohol selected from sucrose, maltose and trehalose; and mixing a cryoprotection composition containing any one organic acid selected from propionic acid, acetic acid and butyric acid with the microorganism cells of the genus Akkermansia; and
Freeze-drying the mixture of the microbial cells, sugar or sugar alcohol and organic acid; A method for producing a freeze-dried powder of microorganisms belonging to the genus Akkermansia comprising a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210174492A KR102643788B1 (en) | 2021-12-08 | 2021-12-08 | Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210174492A KR102643788B1 (en) | 2021-12-08 | 2021-12-08 | Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230086143A true KR20230086143A (en) | 2023-06-15 |
KR102643788B1 KR102643788B1 (en) | 2024-03-07 |
Family
ID=86763627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210174492A KR102643788B1 (en) | 2021-12-08 | 2021-12-08 | Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102643788B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115087727A (en) * | 2019-09-25 | 2022-09-20 | 健康生物公司 | Obligate anaerobic human intestinal microorganisms for cancer treatment and uses thereof |
CN117844715A (en) * | 2024-03-05 | 2024-04-09 | 中国农业科学院农产品加工研究所 | Acremonium muciniphilum culture medium and preparation method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100988809B1 (en) | 2008-11-06 | 2010-10-20 | 주식회사 하이닉스반도체 | Semiconductor memory device and output enable signal generating method |
WO2016177801A1 (en) * | 2015-05-06 | 2016-11-10 | Wageningen Universiteit | Method of culturing akkermansia |
KR101799829B1 (en) | 2016-07-11 | 2017-11-21 | 한국생명공학연구원 | Akkermansia muciniphila strain for preventing or treating degenerative brain disease and uses thereof |
KR101809172B1 (en) | 2016-07-11 | 2017-12-14 | 한국생명공학연구원 | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component |
KR20180133443A (en) * | 2016-04-11 | 2018-12-14 | 바게닝겐 유니버시테이트 | New bacterial species |
KR102222953B1 (en) | 2020-11-11 | 2021-03-04 | 주식회사 엔테로바이옴 | Media supplement for high yield industrial culture of fastidious anaerobes and culture media comprising the same |
KR20210036855A (en) * | 2019-09-25 | 2021-04-05 | (주)헬스바이옴 | Strict anaerobic human gut microbe for antitumor treatment and uses thereof |
KR102290654B1 (en) * | 2021-01-21 | 2021-08-18 | (주)메디톡스 | Cryoprotectant compositions and lactic acid bacteria preparations comprising the same |
-
2021
- 2021-12-08 KR KR1020210174492A patent/KR102643788B1/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100988809B1 (en) | 2008-11-06 | 2010-10-20 | 주식회사 하이닉스반도체 | Semiconductor memory device and output enable signal generating method |
WO2016177801A1 (en) * | 2015-05-06 | 2016-11-10 | Wageningen Universiteit | Method of culturing akkermansia |
KR20180133443A (en) * | 2016-04-11 | 2018-12-14 | 바게닝겐 유니버시테이트 | New bacterial species |
KR101799829B1 (en) | 2016-07-11 | 2017-11-21 | 한국생명공학연구원 | Akkermansia muciniphila strain for preventing or treating degenerative brain disease and uses thereof |
KR101809172B1 (en) | 2016-07-11 | 2017-12-14 | 한국생명공학연구원 | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component |
KR20210036855A (en) * | 2019-09-25 | 2021-04-05 | (주)헬스바이옴 | Strict anaerobic human gut microbe for antitumor treatment and uses thereof |
KR102222953B1 (en) | 2020-11-11 | 2021-03-04 | 주식회사 엔테로바이옴 | Media supplement for high yield industrial culture of fastidious anaerobes and culture media comprising the same |
KR102290654B1 (en) * | 2021-01-21 | 2021-08-18 | (주)메디톡스 | Cryoprotectant compositions and lactic acid bacteria preparations comprising the same |
Non-Patent Citations (2)
Title |
---|
Derrien et al., "Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium" International Journal of Systematic and Evolutionary Microbiology (2004), 54, 1469-1476 |
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY (2004), VOL.54, P.1469-1476 [DOI 10.1099/IJS.0.02873-0]* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115087727A (en) * | 2019-09-25 | 2022-09-20 | 健康生物公司 | Obligate anaerobic human intestinal microorganisms for cancer treatment and uses thereof |
CN117844715A (en) * | 2024-03-05 | 2024-04-09 | 中国农业科学院农产品加工研究所 | Acremonium muciniphilum culture medium and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102643788B1 (en) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2984986C (en) | Method of culturing akkermansia | |
KR102643788B1 (en) | Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it | |
Premaratne et al. | Development of an improved chemically defined minimal medium for Listeria monocytogenes | |
KR101604633B1 (en) | Medium composition for culturing lactic acid bacteria and producing method of powder of lactic acid bacteria using the same | |
KR102222953B1 (en) | Media supplement for high yield industrial culture of fastidious anaerobes and culture media comprising the same | |
CA3005308A1 (en) | Media and fermentation methods for producing polysaccharides in bacterial cell culture | |
US20080274515A1 (en) | Animal component free meningococcal polysaccharide fermentation and seedbank development | |
JPH0956394A (en) | Preparation of hyaluronic acid by fermentation using streptococcus | |
KR20130063253A (en) | The alcohol resistant strain of lactic acid bacteria, pediococcus acidilactici and its use | |
JP2023139253A (en) | Medium supplement for high-yield culture of fastidious anaerobes and medium composition containing the same | |
CN112694976A (en) | Preparation method of lactobacillus acidophilus powder with high viable count | |
KR100902396B1 (en) | Product | |
CN1306025C (en) | Culture medium its rpeparation method and method for culturing lact-streptocin | |
CN113166715A (en) | Use of cysteine or salts of cysteine for protecting lactic acid bacteria against freezing | |
JP2006238706A (en) | Culturing medium of lactobacillus bifidus, method for culturing lactobacillus bifidus by using the same and food added with lactobacillus bifidus cultured by the method | |
ZA200604541B (en) | Cryo-protective agents for microorganisms | |
RU2217493C2 (en) | Biopreparation- probiotic, method for its preparing and strain streptococcus faecium te-17 for preparing biopreparation-probiotic for animals and poultry | |
SU1554173A1 (en) | Method of preparing protein hydrolyzate from keratin-containing raw | |
JPS58224695A (en) | Preparation of l-glutamic acid by fermentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |